Accelerating the Timeline to First-in-human Trials
Accelerating the Timeline to First-in-human Trials: NEW Case Studies on API in Capsule Technology Accurately and precisely dispensing drug substances alone, in tiny amounts as low as 100 micrograms into capsules, excipients or bulking agents is changed the process of drug development. Today, Pharma companies use micro-dosing technology to shorten drug development by reducing the need for costly time-consuming stability and pre-formulation studies. Reducing the time it takes to reach the critical "first in human" clinical decision point allows an increase in throughput of candidate compounds for development, thereby enabling pharma development departments to focus their resources on potential winners. This webinar will feature NEW case studies on the Capsugel technology. Speakers include: David Edwards, Director of Pharmaceutical Technology, Capsugel Tim Scott, President, Pharmatek Laboratories Joseph Forth, Manager, Pharmaceutical Development AMRI
- Presenting
- David Edwards, Capsugel; Tim Scott, Pharmatek Laboratories; Joseph Forth, AMRI
- Channel
- PFQ and Food Quality Webcast Channel
- Date
- Jul 13 2010
- Duration
- 5050
- Tags
- capsugel, xcelodose, micro-dosing, pharma
Flash is required to view this webcast/channel:
You need version 9.0.115.0 or later of the free Flash player from Adobe
to use this content.
To download and install the free player from Adobe's web site
click here.
